University of Zurich spinoff Oncobit AG is developing cancer monitoring tests to improve personalized cancer treatment. It has received certification under the In Vitro Diagnostics Regulation (IVDR) for its Oncobit PM melanoma test suite, paving the way to CE-mark the test and offer it for clinical use.
